Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) General Counsel Iqbal J. Hussain sold 2,080 shares of Centessa Pharmaceuticals stock in a transaction on Monday, April 28th. The stock was sold at an average price of $14.01, for a total transaction of $29,140.80. Following the completion of the sale, the general counsel now owns 105,386 shares of the company's stock, valued at approximately $1,476,457.86. This trade represents a 1.94 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Centessa Pharmaceuticals Stock Down 0.2 %
CNTA stock opened at $13.72 on Wednesday. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm's 50-day simple moving average is $14.32 and its 200 day simple moving average is $15.84. The stock has a market cap of $1.83 billion, a PE ratio of -8.97 and a beta of 1.53. Centessa Pharmaceuticals plc has a fifty-two week low of $7.75 and a fifty-two week high of $19.09.
Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.04. As a group, sell-side analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.
Analyst Upgrades and Downgrades
CNTA has been the topic of a number of recent analyst reports. Guggenheim restated a "buy" rating and issued a $28.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Morgan Stanley reaffirmed an "overweight" rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Piper Sandler assumed coverage on Centessa Pharmaceuticals in a report on Monday, March 31st. They issued an "overweight" rating and a $38.00 price target for the company. Finally, TD Cowen initiated coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a "buy" rating on the stock. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $27.71.
Read Our Latest Analysis on CNTA
Institutional Investors Weigh In On Centessa Pharmaceuticals
A number of institutional investors have recently added to or reduced their stakes in CNTA. GF Fund Management CO. LTD. bought a new stake in shares of Centessa Pharmaceuticals in the 4th quarter worth $31,000. GAMMA Investing LLC raised its position in Centessa Pharmaceuticals by 29.1% in the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock worth $64,000 after acquiring an additional 865 shares in the last quarter. Barclays PLC lifted its holdings in Centessa Pharmaceuticals by 1,414.9% in the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after acquiring an additional 4,952 shares during the last quarter. BNP Paribas Financial Markets bought a new position in shares of Centessa Pharmaceuticals during the 4th quarter valued at about $162,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of Centessa Pharmaceuticals in the 4th quarter worth approximately $171,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.
Centessa Pharmaceuticals Company Profile
(
Get Free Report)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
